IP Strategies
Insights and analysis on building patent portfolios, navigating AI-related IP challenges, and developing strategies that appeal to VC investors and potential acquirers.
Featured
A comprehensive guide to protecting AI infrastructure innovations through patents, including FAQs on hardware vs. software protection, common rejections, and proven filing strategies aligned with USPTO 2026 guidance.
In the race to build the next foundational AI model, your algorithms and architectures are your crown jewels. Here's why patents are the only reliable moat in an industry where code can be reverse-engineered overnight.
The 'AI wrappers have no moat' critique misses a crucial point: patents can protect the novel orchestration, prompt engineering, and system design that make wrapper products valuable. Here's how.
Director Squire's USPTO is signaling a more favorable stance on AI and diagnostics patents. Life science companies should seize this moment to build robust IP portfolios before the window closes.
Director Squire's USPTO is reversing years of restrictive AI patent interpretations. AI infrastructure companies have a unique window to patent innovations previously deemed ineligible.
The 'software patents are dead' narrative is outdated. Director Squire's USPTO guidance opens doors for AI-powered software companies to build defensible patent portfolios.
AI infrastructure companies compete on novel hardware optimizations that can't be easily reverse-engineered. Discover why patents on hardware configurations provide the ultimate moat in this critical emerging technology.
From autonomous vehicles to warehouse robots, physical AI companies face unique IP challenges. Learn why a robust patent portfolio is essential for protecting your hardware-software integration innovations.
Analyzing how model distillation poses unique IP challenges and why patents may be the silver bullet for protecting AI innovations against unauthorized distillation.
Exploring the legal implications of AI-driven drug discovery, including patent eligibility, inventorship challenges, and strategies for pharmaceutical companies to protect their innovations.
All Articles
A comprehensive guide to protecting AI infrastructure innovations through patents, including FAQs on hardware vs. software protection, common rejections, and proven filing strategies aligned with USPTO 2026 guidance.
In the race to build the next foundational AI model, your algorithms and architectures are your crown jewels. Here's why patents are the only reliable moat in an industry where code can be reverse-engineered overnight.
The 'AI wrappers have no moat' critique misses a crucial point: patents can protect the novel orchestration, prompt engineering, and system design that make wrapper products valuable. Here's how.
Director Squire's USPTO is signaling a more favorable stance on AI and diagnostics patents. Life science companies should seize this moment to build robust IP portfolios before the window closes.
Director Squire's USPTO is reversing years of restrictive AI patent interpretations. AI infrastructure companies have a unique window to patent innovations previously deemed ineligible.
The 'software patents are dead' narrative is outdated. Director Squire's USPTO guidance opens doors for AI-powered software companies to build defensible patent portfolios.
AI infrastructure companies compete on novel hardware optimizations that can't be easily reverse-engineered. Discover why patents on hardware configurations provide the ultimate moat in this critical emerging technology.
From autonomous vehicles to warehouse robots, physical AI companies face unique IP challenges. Learn why a robust patent portfolio is essential for protecting your hardware-software integration innovations.
The algorithms that combine LiDAR, camera, and radar data are the secret sauce of autonomous vehicles. Here's how to protect your sensor fusion innovations before competitors reverse-engineer your approach.
If you're a vertical SaaS company integrating AI capabilities, your domain-specific implementations may be more patentable than you think. Here's how to identify and protect your innovations.
After advising dozens of successful VC-backed AI companies, patterns emerge in what sophisticated investors expect from IP strategy. Here's the inside perspective on building a portfolio that attracts funding.
As warehouse robotics becomes commoditized, your manipulation algorithms and gripper designs are key differentiators. Learn patent strategies for protecting physical AI innovations in logistics.
Healthcare AI faces unique governance challenges at the intersection of FDA regulations and patent law. Learn how to build compliant AI systems while protecting your diagnostic and therapeutic innovations.
Sophisticated prompt chains and AI orchestration systems represent genuine technical innovation. Learn when these systems cross the threshold from trade secrets to patentable inventions.
The DeepSeek controversy exposed a critical vulnerability: if competitors can distill your model's capabilities, trade secrets offer zero protection. Here's why patents are the only viable defense.
Custom silicon for AI inference is a battleground of IP. From novel architectures to efficient model deployment, here's how robotics companies can build defensible patent portfolios around edge AI.
Your industry-specific training data won't protect you forever. As foundation models improve, vertical AI companies need patent strategies that protect their domain expertise and specialized algorithms.
Key mistakes life sciences companies make when developing AI governance frameworks, from patent inventorship complexities to inadequate documentation standards.
In M&A due diligence, acquirers scrutinize IP assets more than any other factor. Learn how strategic patent development can dramatically increase your company's valuation and negotiating leverage.
Financial services AI must navigate strict regulatory requirements while building defensible IP. Here's how to document AI systems for both compliance and patent purposes in the fintech space.
Examining IP protection strategies including contractual safeguards, copyright considerations, and patent law in the rapidly commoditizing AI landscape.
Analyzing how model distillation poses unique IP challenges and why patents may be the silver bullet for protecting AI innovations against unauthorized distillation.
Understanding how patenting drugs discovered with AI assistance requires significant human contribution, and strategies for startups and big pharma to navigate these challenges.
Comprehensive guide on IP risks, licensing considerations, M&A due diligence, and documentation practices for companies using AI in drug discovery.
Diving into the Thaler v. Vidal decision and what it means for the future of life sciences and technology patents when AI assists in innovation.
Exploring considerations for companies large and small innovating in AI drug discovery, including ensuring human contribution and assessing third-party AI tools.
Exploring the legal implications of AI-driven drug discovery, including patent eligibility, inventorship challenges, and strategies for pharmaceutical companies to protect their innovations.
Analyzing the Cardionet decision and potential avenues to patent eligibility for diagnostic inventions involving improved devices or laboratory techniques.
Browse by Industry